Tonix Pharmaceuticals Holding Corp. (TNXP)Healthcare | Biotechnology | Berkeley Heights, United States | NasdaqGS
11.71 USD
-0.83
(-6.584%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 11.45 -0.26 (-0.255%) ⇩ (July 13, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:15 a.m. EDT
The investment case here is fundamentally broken. The company has endured a catastrophic multi-year decline, losing nearly 100% of its value over the last nine years, with four consecutive years of negative annual returns ending recently. Despite a recent spike in revenue growth, the business is hemorrhaging cash with massive negative operating and free cash flows, and the balance sheet is effectively worthless given the debt load relative to the tiny market cap. The negative forward P/E confirms that analysts see no path to profitability soon. While insiders and directors have been buying shares recently, this likely reflects distress selling or mandatory conversions rather than a belief in a turnaround, especially given the overwhelming options positioning for further downside. The statistical forecast also leans negative, aligning with the bleak fundamental reality. This is a deep value trap where the market has correctly priced out any hope of recovery. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.075604 |
| AutoARIMA | 0.076482 |
| MSTL | 0.077886 |
| AutoETS | 0.078156 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.655 |
| Excess Kurtosis | -0.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.568 |
| Revenue per Share | 1.679 |
| Market Cap | 186,587,072 |
| Forward P/E | -1.50 |
| Beta | 1.65 |
| Website | https://www.tonixpharma.com |
As of July 11, 2026, 3:15 a.m. EDT: Speculators are heavily positioned for downside protection, with out-of-the-money put open interest significantly dominating call open interest across all expirations. While there is some call volume at the $15 strike, the overwhelming concentration of option interest is in puts, particularly at strikes below the current price, indicating a strong speculative bias toward further declines rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7071061 |
| Address1 | 200 Connell Drive |
| Address2 | Suite 3100 |
| All Time High | 19,200,000,000.0 |
| All Time Low | 6.76 |
| Ask | 14.28 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 544,720 |
| Average Daily Volume3 Month | 494,039 |
| Average Volume | 494,039 |
| Average Volume10Days | 544,720 |
| Beta | 1.653 |
| Bid | 9.0 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 15.989 |
| City | Berkeley Heights |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.705 |
| Current Ratio | 6.988 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 12.71 |
| Day Low | 11.04 |
| Debt To Equity | 0.568 |
| Display Name | Tonix Pharmaceuticals Holding |
| Dividend Date | 1,572,566,400 |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,786,392,000 |
| Earnings Timestamp Start | 1,786,392,000 |
| Ebitda | -149,199,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.016 |
| Enterprise To Revenue | 0.137 |
| Enterprise Value | 2,407,075 |
| Eps Current Year | -10.1 |
| Eps Forward | -7.8 |
| Eps Trailing Twelve Months | -13.7 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.7082 |
| Fifty Day Average Change | -1.0032005 |
| Fifty Day Average Change Percent | -0.078941196 |
| Fifty Two Week Change Percent | -70.71061 |
| Fifty Two Week High | 69.97 |
| Fifty Two Week High Change | -58.265 |
| Fifty Two Week High Change Percent | -0.832714 |
| Fifty Two Week Low | 10.03 |
| Fifty Two Week Low Change | 1.6750002 |
| Fifty Two Week Low Change Percent | 0.16699903 |
| Fifty Two Week Range | 10.03 - 69.97 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,336,656,600,000 |
| Float Shares | 15,012,249 |
| Forward Eps | -7.8 |
| Forward P E | -1.500641 |
| Free Cashflow | -76,727,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 142 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.58561003 |
| Gross Profits | 10,281,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00137 |
| Held Percent Institutions | 0.45793998 |
| Implied Shares Outstanding | 15,940,801 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,738,713,600 |
| Last Split Factor | 1:100 |
| Long Business Summary | Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey. |
| Long Name | Tonix Pharmaceuticals Holding Corp. |
| Market | us_market |
| Market Cap | 186,587,072 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_112008811 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -147,386,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 199,658,532 |
| Number Of Analyst Opinions | 5 |
| Open | 12.51 |
| Operating Cashflow | -125,583,000 |
| Operating Margins | -6.03911 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 862 799 8599 |
| Post Market Change | -0.2550001 |
| Post Market Change Percent | -2.1785572 |
| Post Market Price | 11.45 |
| Post Market Time | 1,783,986,964 |
| Previous Close | 12.53 |
| Price Eps Current Year | -1.1589109 |
| Price Hint | 2 |
| Price To Book | 0.7320658 |
| Price To Sales Trailing12 Months | 10.628108 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.569 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.825 |
| Regular Market Change Percent | -6.5842 |
| Regular Market Day High | 12.71 |
| Regular Market Day Low | 11.04 |
| Regular Market Day Range | 11.04 - 12.71 |
| Regular Market Open | 12.51 |
| Regular Market Previous Close | 12.53 |
| Regular Market Price | 11.705 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,024,107 |
| Return On Assets | -0.41923 |
| Return On Equity | -0.72331 |
| Revenue Growth | 1.832 |
| Revenue Per Share | 1.679 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 15,940,801 |
| Shares Percent Shares Out | 0.22469999 |
| Shares Short | 3,582,293 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,867,066 |
| Short Name | Tonix Pharmaceuticals Holding C |
| Short Percent Of Float | 0.225 |
| Short Ratio | 5.9 |
| Source Interval | 15 |
| State | NJ |
| Symbol | TNXP |
| Target High Price | 65.0 |
| Target Low Price | 22.0 |
| Target Mean Price | 42.2 |
| Target Median Price | 34.0 |
| Total Cash | 185,470,000 |
| Total Cash Per Share | 11.635 |
| Total Debt | 1,290,000 |
| Total Revenue | 17,556,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -13.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.77285 |
| Two Hundred Day Average Change | -4.06785 |
| Two Hundred Day Average Change Percent | -0.25790203 |
| Type Disp | Equity |
| Volume | 1,024,107 |
| Website | https://www.tonixpharma.com |
| Zip | 7,928 |